Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition - PubMed (original) (raw)
. 2015 Mar 10;4(3):360-73.
doi: 10.1016/j.stemcr.2015.01.006. Epub 2015 Feb 13.
Yohei Okada 2, Soraya Nishimura 1, Takashi Sasaki 3, Go Itakura 1, Yoshiomi Kobayashi 1, Francois Renault-Mihara 1, Atsushi Shimizu 4, Ikuko Koya 5, Rei Yoshida 6, Jun Kudoh 7, Masato Koike 8, Yasuo Uchiyama 8, Eiji Ikeda 9, Yoshiaki Toyama 6, Masaya Nakamura 10, Hideyuki Okano 11
Affiliations
- PMID: 25684226
- PMCID: PMC4375796
- DOI: 10.1016/j.stemcr.2015.01.006
Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition
Satoshi Nori et al. Stem Cell Reports. 2015.
Abstract
Previously, we described the safety and therapeutic potential of neurospheres (NSs) derived from a human induced pluripotent stem cell (iPSC) clone, 201B7, in a spinal cord injury (SCI) mouse model. However, several safety issues concerning iPSC-based cell therapy remain unresolved. Here, we investigated another iPSC clone, 253G1, that we established by transducing OCT4, SOX2, and KLF4 into adult human dermal fibroblasts collected from the same donor who provided the 201B7 clone. The grafted 253G1-NSs survived, differentiated into three neural lineages, and promoted functional recovery accompanied by stimulated synapse formation 47 days after transplantation. However, long-term observation (for up to 103 days) revealed deteriorated motor function accompanied by tumor formation. The tumors consisted of Nestin(+) undifferentiated neural cells and exhibited activation of the OCT4 transgene. Transcriptome analysis revealed that a heightened mesenchymal transition may have contributed to the progression of tumors derived from grafted cells.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
Graphical abstract
Figure 1
Grafted 253G1-NSs Mainly Differentiate into Neurons and Form Synapses with Host Spinal Cord Neurons (A and B) Venus+ 253G1-NSs integrated into the mouse spinal cord. Arrowheads indicate the lesion epicenter. (C–F) Representative images of Venus+ grafted cells immunostained for the markers NeuN (mature neurons) (C), βIII tubulin (all neurons) (D), GFAP (astrocytes) (E), and APC (oligodendrocytes) (F). (G) Percentages of cell-type-specific marker-positive cells among Venus+ grafted cells at 47 days post-transplantation. Values are expressed as the mean ± SEM (n = 4 mice). (H) Most 253G1-derived neurons differentiated into GAD67+ (GABAergic) neurons. (I and J) TH+/HNu+ neurons and ChAT+/HNu+ neurons were observed, but were rare. (K) Sections were triple stained for HNu (green), βIII tubulin (red), and the presynaptic marker Bassoon (Bsn, white). The Bsn antibody recognized the mouse, but not the human, protein. (L) Sections triple stained for HNu (green), βIII tubulin (red), and the human-specific presynaptic marker hSyn (white). βIII tubulin+/HNu− neurons represented host mouse neurons. The hSyn antibody recognized the human, but not the mouse, protein. (M) Large numbers of somatic and dendritic terminals from graft-derived nerve cells were present on host ChAT+ motor neurons at the ventral horns. (N) Electron microscopy (EM) images show synapse formation between host mouse neurons and graft-derived Venus+ (black) human neurons. Pre- and post-synaptic structures indicate transmission from a graft-derived neuron to a host neuron, and from a host neuron to a graft-derived neuron. H, host neuron; G, graft-derived neuron; arrowheads, post-synaptic density. (O) Motor function in the hind limbs was assessed weekly using the BMS score until 47 days post-transplantation. Values are expressed as the mean ± SEM (n = 32 mice). (P) Rotarod test 47 days after transplantation. Graph shows total run time. Values are expressed as the means ± SEM (n = 10 mice). (Q) Treadmill gait analysis using the DigiGait system 47 days post-transplantation. Graph shows stride length. Values are expressed as the means ± SEM (n = 19 mice). Behavioral analyses were performed by two observers who were blinded to the treatment conditions. Scale bars, 1,000 μm in (A); 100 μm in (B); 50 μm in (J-1); 20 μm in (F-3), (F-4), (H-1), (J-2), (K-1), (L-1), and (M-1); 10 μm in (H-2), (J-3), (K-2), (L-2), and (M-2); 0.5 μm in (N). See also Figure S1.
Figure 2
Tumor Formation during Long-Term Observation after 253G1-NS Transplantation (A) Up to 103 days post-transplantation, motor function in the hind limbs was assessed weekly using the BMS score. Values are expressed as the means ± SEM (n = 32 mice up to 47 days post-transplantation; thereafter, n = 22 mice until 103 days post-transplantation). (B) Representative in vivo images of mice at 0, 14, 42, 70, and 103 days after 253G1-NS transplantation. (C) Quantitative analysis of photon counts derived from grafted cells. Values are expressed as the means ± SEM (n = 20 mice up to 42 days post-transplantation; thereafter, n = 14 mice until 103 days post-transplantation). (D) Representative hematoxylin and eosin (H&E) image of a large tumor (700 μm < ϕ). (E) Boxed area in (D). (E1–E3) Immunohistochemistry showing that most grafted cells in the microcystic area were Nestin+. (F) Representative H&E image of a medium tumor (200 < ϕ < 700 μm). (G) Boxed area in (F). Immunohistochemistry shows that some grafted cells exhibited normal neural differentiation. (H and I) Boxed area in (F). Some grafted cells formed microcystic masses that were positive for Nestin. (J) Percentages of cell-type-specific, marker-positive cells among HNu+ grafted cells at 103 days post-transplantation. Values represent the means ± SEM (n = 4 and 10 mice for 47 and 103 days post-transplantation, respectively). ∗p < 0.05, ∗∗p < 0.01. Scale bars, 500 μm in (D) and (F), 50 μm in (E) and (G–I). See also Figure S2.
Figure 3
Histological and Gene-Expression Analyses of Tumors (A) Schematic of histological analyses of tumors. (B) Correlation between tumor diameter and the proportion of grafted cells that were Nestin+ at 47 and 103 days post-transplantation (TP). (C) Correlation between tumor diameter and the proportion of grafted cells that were Ki-67+. (D) Correlation between tumor diameter and the proportion of grafted cells that were OCT4+. (E) Correlation between the tumor diameter and the proportion of grafted cells that were OCT4+/HNu+ at 103 days after TP. (F) Correlation between the number of days after TP (47 or 103 days after TP) and the proportion of grafted cells that were OCT4+. In (B)–(F), n indicates the number of mice. (G) Schematic of mRNA expression analyses of tumors. (H–M) The expression of human _OCT4_-Tg, _OCT4_-Endo, _SOX2_-Tg, _SOX2_-Endo, _KLF4_-Tg, _KLF4_-Endo, c-_MYC_-Tg, and _c-MYC_-Endo mRNA in 253G1 cells, 253G1-NSs, 103-day post-transplant 253G1-NSs (TP 103d), and adult human dermal fibroblasts (HDFs) was analyzed by RT-PCR. Data are presented as expression levels relative to the control (HDFs) 11 days after retroviral transduction of OCT4, SOX2, KLF4, and c-MYC. Values represent the means ± SEM (n = 3 independent experiments). The p values shown in (B)–(F) were calculated using Scheffe’s test, and p values to determine significance were calculated using the Kruskal-Wallis non-parametric test: (B) 5.00E-06, (C) 7.20E-06, (D) 0.01, and (F) 1.33E-04. ∗p < 0.05, ∗∗p < 0.01. ns, non-significant.
Figure 4
Global Human Gene-Expression Analysis (A) Hierarchical clustering analysis of mouse gene-expression data from spinal cord tissues of the PBS-5d and -103d, 253G1-NS/TP-5d and -103d, and 201B7-NS/TP-5d and -103d groups. (B) Hierarchical clustering analysis of human gene-expression data: 253G1-NSs and 201B7-NSs, as well as spinal cord tissues of the 253G1-NS/TP-5d and -103d, and 201B7-NS/TP-5d and -103d groups. In (A) and (B), the signal intensity of each gene is displayed as a heatmap colored according to the expression level. (C) Principal-component analysis (PCA) of human gene-expression data. x axis, component 1 (41.03%); y axis, component 2 (24.21%); z axis, component 3 (13.88%). (D) Two-dimensional PCA of human gene expression data. x axis, component 1 (41.03%); y axis, component 2 (24.21%). (E) Venn diagram of human genes whose expression increased in the 253G1-NS/TP-103d and 201B7-NS/TP-103d groups relative to 253G1-NSs and 201B7-NSs. Color key: red, 692 genes highly expressed in the 253G1-NS/TP-103d group; blue, 335 genes highly expressed in the 201B7-NS/TP-103d group; purple, 1,023 genes highly expressed in both the 253G1- and 201B7-NS/TP-103d groups. (F–L) EMT-related human gene expression in 253G1- and 201B7-NSs and the 253G1- and 201B7-NS/TP-103d groups. Values represent the means ± SEM (n = 1 each in the human iPSC-NS, n = 2 for 201B7-NS/TP-103d, and n = 3 for 253G1-NS/TP-103d; n indicates the number of independent experiments). (M–P) The expression of SNAI1, SNAI2, TWIST1, and TWIST2 mRNA in 201B7-NSs and 253G1-NSs was analyzed by RT-PCR. Data are presented as expression levels relative to the control (the U87 human glioblastoma cell line). Values represent the means ± SEM (n = 3 independent experiments). (Q) Representative H&E image of the mid-sagittal section 103 days after transplantation. (R) p-STAT3-stained image of the adjacent section of (Q). Arrow, lesion epicenter; arrowhead, distribution of grafted 253G1-NSs. (S) Boxed area in (R). Scale bar, 1,000 μm in (Q) and (R), 100 μm in (S). ∗p < 0.05, ∗∗p < 0.01. See also the mRNA-seq read distribution in Table S1.
Figure 5
The Most Significantly Altered Common Pathways after Transplantation of 253G1- and 201B7-NSs, as Revealed by Ingenuity Pathway Analysis Canonical pathway analysis identified the pathways from the Ingenuity Pathway Analysis library that were significantly enriched in the data set. Only genes that showed a fold change ≥ 3.0 were considered in this analysis. The black bars show the human gene set in the 253G1-NS/TP-103d group versus the 201B7-NS/TP-103d group. The white bars show the comparison of the human gene set in 253G1-NSs versus 201B7-NSs in the same pathway. Bars represent the logarithmic values (log10) of the significance level (p); the solid line corresponds to the threshold of p = 0.05.
Similar articles
- Human neural progenitors derived from integration-free iPSCs for SCI therapy.
Liu Y, Zheng Y, Li S, Xue H, Schmitt K, Hergenroeder GW, Wu J, Zhang Y, Kim DH, Cao Q. Liu Y, et al. Stem Cell Res. 2017 Mar;19:55-64. doi: 10.1016/j.scr.2017.01.004. Epub 2017 Jan 5. Stem Cell Res. 2017. PMID: 28073086 Free PMC article. - Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity.
Kobayashi Y, Okada Y, Itakura G, Iwai H, Nishimura S, Yasuda A, Nori S, Hikishima K, Konomi T, Fujiyoshi K, Tsuji O, Toyama Y, Yamanaka S, Nakamura M, Okano H. Kobayashi Y, et al. PLoS One. 2012;7(12):e52787. doi: 10.1371/journal.pone.0052787. Epub 2012 Dec 27. PLoS One. 2012. PMID: 23300777 Free PMC article. - Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice.
Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, Kobayashi Y, Fujiyoshi K, Koike M, Uchiyama Y, Ikeda E, Toyama Y, Yamanaka S, Nakamura M, Okano H. Nori S, et al. Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16825-30. doi: 10.1073/pnas.1108077108. Epub 2011 Sep 26. Proc Natl Acad Sci U S A. 2011. PMID: 21949375 Free PMC article. - [Therapeutic potential of induced pluripotent stem cells for spinal cord injury].
Nori S, Tsuji O, Okada Y, Toyama Y, Okano H, Nakamura M. Nori S, et al. Brain Nerve. 2012 Jan;64(1):17-27. Brain Nerve. 2012. PMID: 22223498 Review. Japanese. - iPSC-derived neural precursor cells: potential for cell transplantation therapy in spinal cord injury.
Nagoshi N, Okano H. Nagoshi N, et al. Cell Mol Life Sci. 2018 Mar;75(6):989-1000. doi: 10.1007/s00018-017-2676-9. Epub 2017 Oct 9. Cell Mol Life Sci. 2018. PMID: 28993834 Free PMC article. Review.
Cited by
- CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy.
Huang J, Yang Q, Wang W, Huang J. Huang J, et al. Front Immunol. 2024 Apr 11;15:1378739. doi: 10.3389/fimmu.2024.1378739. eCollection 2024. Front Immunol. 2024. PMID: 38665921 Free PMC article. Review. - Human-induced pluripotent stem cell-derived neural stem/progenitor cell ex vivo gene therapy with synaptic organizer CPTX for spinal cord injury.
Saijo Y, Nagoshi N, Kawai M, Kitagawa T, Suematsu Y, Ozaki M, Shinozaki M, Kohyama J, Shibata S, Takeuchi K, Nakamura M, Yuzaki M, Okano H. Saijo Y, et al. Stem Cell Reports. 2024 Mar 12;19(3):383-398. doi: 10.1016/j.stemcr.2024.01.007. Epub 2024 Feb 15. Stem Cell Reports. 2024. PMID: 38366597 Free PMC article. - Graft-derived neurons and bystander effects are maintained for six months after human iPSC-derived NESC transplantation in mice's cerebella.
Mendonça LS, Henriques D, Fernandes V, Moreira R, Brás J, Duarte S, Schwamborn JC, de Almeida LP. Mendonça LS, et al. Sci Rep. 2024 Feb 8;14(1):3236. doi: 10.1038/s41598-024-53542-x. Sci Rep. 2024. PMID: 38332227 Free PMC article. - Preclinical long-term safety of intraspinal transplantation of human dorsal spinal GABA neural progenitor cells.
Zheng X, Liu Z, He Z, Xu J, Wang Y, Gong C, Zhang R, Zhang SC, Chen H, Wang W. Zheng X, et al. iScience. 2023 Oct 23;26(11):108306. doi: 10.1016/j.isci.2023.108306. eCollection 2023 Nov 17. iScience. 2023. PMID: 38026209 Free PMC article. - Regulation of the JAK/STAT signaling pathway in spinal cord injury: an updated review.
Guo X, Jiang C, Chen Z, Wang X, Hong F, Hao D. Guo X, et al. Front Immunol. 2023 Nov 8;14:1276445. doi: 10.3389/fimmu.2023.1276445. eCollection 2023. Front Immunol. 2023. PMID: 38022526 Free PMC article. Review.
References
- Abou-Ghazal M., Yang D.S., Qiao W., Reina-Ortiz C., Wei J., Kong L.Y., Fuller G.N., Hiraoka N., Priebe W., Sawaya R., Heimberger A.B. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin. Cancer Res. 2008;14:8228–8235. - PMC - PubMed
- Bradford J.R., Farren M., Powell S.J., Runswick S., Weston S.L., Brown H., Delpuech O., Wappett M., Smith N.R., Carr T.H. RNA-seq differentiates tumour and host mRNA expression changes induced by treatment of human tumour xenografts with the VEGFR tyrosine kinase inhibitor Cediranib. PLoS ONE. 2013;8:e66003. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical